Avalo Therapeutics, Inc. (AVTX)
NasdaqCM · USD · Healthcare · Biotechnology
$6.69 (-1.26%) as of
Key statistics
- Market cap
- 358.52M
- Forward P/E
- -2.41
- EPS (TTM)
- -4.31
- Dividend yield
- 0.00%
- 52-week range
- 6.53 – 24.27
- Beta
- 0.69
- Revenue (TTM)
- 59k
- Profit margin
- 0.00%
- Analyst target
- $36.60
- Volume
- 1.27M
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Wayne, PA, United States
- Employees
- 33
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.